The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).
Aamer Farooq
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Todd L. Demmy
No relevant relationships to disclose
Paul Bogner
No relevant relationships to disclose
Cynthia Nowadly
No relevant relationships to disclose
Wei Tan
No relevant relationships to disclose
Hongbin Chen
No relevant relationships to disclose
Saikrishna S. Yendamuri
No relevant relationships to disclose
Chukwumere E. Nwogu
No relevant relationships to disclose
Peter Walter Bushunow
No relevant relationships to disclose
Alex A. Adjei
No relevant relationships to disclose
Nithya Ramnath
No relevant relationships to disclose